MedPath

Millendo Therapeutics, Inc.

Millendo Therapeutics, Inc. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
2011-01-01
Employees
11
Market Cap
-
Website
http://www.millendo.com

Clinical Trials

5

Active:3
Completed:2

Trial Phases

2 Phases

Phase 1:4
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (80.0%)
Phase 2
1 (20.0%)

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

Phase 2
Completed
Conditions
Congenital Adrenal Hyperplasia
Interventions
Drug: ATR-101
First Posted Date
2016-06-17
Last Posted Date
2021-03-10
Lead Sponsor
Millendo Therapeutics, Inc.
Target Recruit Count
10
Registration Number
NCT02804178
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

and more 3 locations

Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma

Phase 1
Completed
Conditions
Adrenal Cancer
ACC
Adrenocortical Carcinoma
Interventions
Drug: ATR-101
First Posted Date
2013-07-12
Last Posted Date
2017-11-06
Lead Sponsor
Millendo Therapeutics, Inc.
Target Recruit Count
63
Registration Number
NCT01898715
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

National Institutes of Health/National Cancer Institute, Bethesda, Maryland, United States

🇺🇸

University of Michigan Cancer Center, Ann Arbor, Michigan, United States

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.